Tirzepatide normalizes diabetic kidney disease through PI3K/AKT antioxidant signaling at 1/3 semaglutide dose
Tirzepatide at 1/3 the dose of semaglutide equally reduced kidney injury markers and oxidative stress in diabetic nephropathy mice, working through PI3K/AKT pathway activation that was reversed by PI3K inhibition.
Quick Facts
What This Study Found
Tirzepatide 1/3 dose = semaglutide for: ↓glucose, ↓weight, ↓UACR. Insulin: could not restore UACR. RNA-seq: PI3K-AKT enriched. Tirzepatide: regulated oxidative stress via PI3K-AKT in podocytes. PI3K inhibitor: reversed antioxidative effect. DN treatment advantage over insulin.
Key Numbers
How They Did This
DN mouse model. Tirzepatide, semaglutide, insulin comparison. RNA-seq of renal tissue. Mouse podocyte cell-5 (MPC5) high glucose experiments. PI3K inhibitor validation.
Why This Research Matters
Diabetic nephropathy leads to dialysis for millions. Tirzepatide achieving equal kidney protection at lower dose—where insulin fails for proteinuria—positions dual agonism as a superior approach for diabetic kidney disease.
The Bigger Picture
The finding that insulin cannot restore proteinuria while GLP-1/GIP drugs can highlights that incretin-based kidney protection goes beyond glucose control—these drugs have direct renoprotective mechanisms.
What This Study Doesn't Tell Us
Mouse model. RNA-seq pathway enrichment is associative. Single PI3K inhibitor used. Short treatment duration. Podocyte cells may not represent all kidney cell types.
Questions This Raises
- ?Is the PI3K-AKT mechanism unique to tirzepatide or shared with semaglutide?
- ?Should tirzepatide replace insulin for DN management?
- ?Would combining tirzepatide with direct PI3K activators enhance renoprotection?
Trust & Context
- Key Stat:
- Insulin fails where tirzepatide succeeds Tirzepatide at 1/3 dose restored kidney proteinuria markers where insulin treatment could not—through PI3K/AKT antioxidant signaling
- Evidence Grade:
- Preclinical with RNA-seq mechanism discovery and pharmacological validation. Good mechanistic study.
- Study Age:
- Published in 2025.
- Original Title:
- GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.
- Published In:
- International immunopharmacology, 146, 113877 (2025)
- Authors:
- Tian, Yan, Tian, Ruixue(2), Juan, He, Guo, Yafan, Yan, Pan, Cheng, Yao, Li, Rongshan, Wang, Baodong
- Database ID:
- RPEP-13808
Evidence Hierarchy
Frequently Asked Questions
Can tirzepatide protect kidneys better than insulin?
In this study, yes. While insulin controlled blood sugar in diabetic mice, it failed to reduce protein leaking into urine (proteinuria)—a key marker of kidney damage. Tirzepatide at one-third the dose of semaglutide successfully reduced proteinuria through a specific antioxidant pathway (PI3K/AKT).
Why does tirzepatide work at a lower dose?
Tirzepatide activates both GLP-1 and GIP receptors. This dual stimulation apparently provides more efficient kidney protection—achieving the same results as semaglutide (which only activates GLP-1) at one-third the dose. The PI3K/AKT antioxidant pathway appears to be more strongly activated by dual agonism.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13808APA
Tian, Yan; Tian, Ruixue; Juan, He; Guo, Yafan; Yan, Pan; Cheng, Yao; Li, Rongshan; Wang, Baodong. (2025). GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.. International immunopharmacology, 146, 113877. https://doi.org/10.1016/j.intimp.2024.113877
MLA
Tian, Yan, et al. "GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress.." International immunopharmacology, 2025. https://doi.org/10.1016/j.intimp.2024.113877
RethinkPeptides
RethinkPeptides Research Database. "GLP-1/GIP dual agonist tirzepatide normalizes diabetic nephr..." RPEP-13808. Retrieved from https://rethinkpeptides.com/research/tian-2025-glp1gip-dual-agonist-tirzepatide-2
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.